![]() |
市場調查報告書
商品編碼
1492224
骨轉移市場:按治療類型、類型、最終用戶、適應症分類 - 全球預測 2024-2030Bone Metastasis Market by Treatment Type (Medications, Therapy), Type (Mixed Bone Metastasis, Osteoblastic Bone Metastasis, Osteolytic Bone Metastasis), End-User, Indication - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年骨轉移市場規模為182.4億美元,預計2024年將達196.2億美元,2030年將達306.6億美元,複合年成長率為7.69%。
當癌細胞從原來的部位擴散到骨骼時,就會發生骨轉移。與從骨骼開始的原發性骨癌不同,骨轉移意味著癌症從身體的其他部位開始,然後轉移到骨骼。許多不同類型的癌症都可能發生這種情況,包括乳癌、攝護腺癌和肺癌。當癌細胞侵入骨骼時,它們會破壞骨骼的正常健康和強度,通常會導致疼痛、骨折和其他嚴重的骨骼問題。轉移性癌細胞會造成正常骨組織分解和再生過程的不平衡,進而削弱骨骼。全球癌症發病率的快速上升、多項癌症意識項目的激增以及全球人口老化正在推動市場成長。然而,骨轉移治療的商業化和產品標準化有限以及骨轉移治療產品開拓的複雜性可能會阻礙市場成長。然而,診斷成像技術的進步以及人工智慧和機器學習在治療個人化和預測分析中的引入可能會為骨轉移市場創造成長機會。
主要市場統計 | |
---|---|
基準年[2023] | 182.4億美元 |
預測年份 [2024] | 196.2億美元 |
預測年份 [2030] | 306.6億美元 |
複合年成長率(%) | 7.69% |
區域洞察
在美洲,尤其是美國和加拿大,乳癌和攝護腺癌等容易轉移到骨骼的癌症盛行率很高。這增加了對先進治療方法和診斷的需求。這些地區的患者和醫療保健提供者重視用於早期檢測的綜合護理以及創新成像和分子診斷技術。在美洲,臨床試驗正在進行中,主要重點是降低與骨轉移相關的發生率,並且正在投入大量投資來研究新的治療方法。歐洲國家為不同的患者群體提供服務,由於不同的遺傳背景和醫療基礎設施,他們需要個人化的治療選擇。歐盟國家受益於全民健康保險,該保險通常涵蓋癌症治療,包括骨轉移的高級治療。患者可以獲得相對容易獲得的醫療保健服務,包括新藥物和技術。根據「歐洲地平線」計畫並在歐盟委員會的資助下,多項研究合作旨在加強整個歐盟的癌症診斷和治療。在中東和非洲地區,雖然海灣國家保持著高標準的醫療保健,但非洲國家往往資源有限,醫療設施和可及性水準參差不齊。世界各地的非政府組織也正在採取一系列舉措來加強非洲的癌症治療。亞太地區的人口正在老化,特別是在日本和中國,由於癌症意識的增強和醫療基礎設施的改善,印度等國家的癌症發生率正在上升。亞太地區對具有成本效益的治療的需求正在增加。各國正致力於生產昂貴藥物的學名藥,以使治療更容易取得。
FPNV定位矩陣
FPNV 定位矩陣對於評估骨轉移市場供應商的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對骨轉移市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在骨轉移市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[182 Pages Report] The Bone Metastasis Market size was estimated at USD 18.24 billion in 2023 and expected to reach USD 19.62 billion in 2024, at a CAGR 7.69% to reach USD 30.66 billion by 2030.
Bone metastasis arises when cancer cells spread from their original site to the bone. Unlike primary bone cancer, which begins in the bones, bone metastasis means the cancer originated elsewhere in the body and then traveled to the bone. This can occur in various types of cancer, including breast, prostate, and lung cancers. When cancer cells invade the bone, they can interfere with the usual health and strength of the bone, often leading to pain, fractures, and severe other bone problems. The metastatic cancer cells can create an imbalance in the normal bone tissue breakdown and regeneration process, weakening bones. Burgeoning incidences of cancer globally, the surge in several cancer awareness programs, and global population aging drive the market growth. However, limited commercialization and product standardization in bone metastasis treatments and complexities in product development for bone metastasis treatments can deter market growth. Nevertheless, advancements in diagnostic imaging technologies and the incorporation of AI and machine learning in treatment personalization and predictive analytics create potential opportunities for bone metastasis market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 18.24 billion |
Estimated Year [2024] | USD 19.62 billion |
Forecast Year [2030] | USD 30.66 billion |
CAGR (%) | 7.69% |
Regional Insights
In the Americas, particularly in the United States and Canada, there is a high prevalence of cancers such as breast and prostate, which are prone to metastasize to bones. This escalates the demand for advanced therapies and diagnostics. Patients and healthcare providers in these regions emphasize integrated care and innovative imaging and molecular diagnostics technologies for early detection. The Americas sees significant investment in research on novel treatments, with ongoing clinical trials primarily focused on reducing the morbidity associated with bone metastases. European countries deal with a diverse patient demographic needing personalized treatment options due to varied genetic backgrounds and healthcare infrastructures. EU countries benefit from universal healthcare systems, which generally cover cancer care, including advanced treatments for bone metastasis. Patients have relatively more accessible healthcare services, including new drugs and technologies. Multiple EU-wide collaborations aim to enhance cancer diagnosis and treatment, supported by funding from the European Commission under Horizon Europe programs. The MEA region sees a variance in healthcare facilities and accessibility, with the Gulf countries maintaining high standards of care, whereas African countries often grapple with resource limitations. Global NGOs also have numerous initiatives to enhance cancer care in Africa. The Asia-Pacific region witnesses a rising incidence of cancer due to aging populations, particularly in Japan and China, combined with increasing awareness and improving healthcare infrastructures in countries including India. In Asia-Pacific, there is a growing demand for cost-effective treatments. Countries focus on manufacturing generic versions of expensive drugs, making treatments more accessible.
Market Insights
The market dynamics represent an ever-changing landscape of the Bone Metastasis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bone Metastasis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bone Metastasis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Greenlights First Denosumab Biosimilars, Expanding Treatment Options for Bone-Related Disorders
The FDA has approved Wyost/Jubbonti (denosumab-body; GP2411), marking the introduction of the first biosimilars to Xgeva/Prolia (denosumab) in the United States. In 2023, these biosimilars, produced by Sandoz, are set to manage osteoporosis, and hypercalcemia prevent in patients with bone metastases from solid tumors. This approval, which closely follows a similar sanction in Canada, positions Wyost/Jubbonti as a pioneering option in the U.S. market, especially notable as no denosumab biosimilars have yet to be approved by the European Union. [Published On: 2024-03-05]
FDA ApprovesMedtronic PLC.'s Enhanced OsteoCool 2.0 System for Bone Tumor Ablation
Medtronic PLC. has received FDA approval for OsteoCool 2.0, an advanced version of its radiofrequency ablation system designed to treat bone tumors, including metastatic cancers and benign lesions like osteoid osteomas. This updated system features a doubling of probe capacity, enabling the use of four internally cooled probes. This improvement allows for the simultaneous treatment of two vertebrae or the creation of larger ablation zones in non-spinal regions. Such advancements facilitate more efficient and extensive treatment options for patients suffering from painful bone tumors often associated with primary cancers of the breast, prostate, or lungs. [Published On: 2024-03-04]
Strategic Acquisition by Telix Pharmaceuticals Limited to Enhance Bone Cancer Treatment Options with QSAM Biosciences, Inc.' Innovative Radiopharmaceutical Platform
Telix Pharmaceuticals Limited officially announced its acquisition of QSAM Biosciences, Inc., a U.S.-based firm focusing on radiopharmaceutical development for treating primary and metastatic bone cancer. Central to this acquisition is QSAM's leading investigational drug, Samarium-153-DOTMP (153Sm-DOTMP), a bone-targeting radiopharmaceutical designed for dual purposes: alleviating pain in bone metastases and treating osteosarcoma, including pediatric cases. This therapeutic candidate significantly advances existing treatments by offering a superior safety profile, enhanced delivery precision, and streamlined production processes. [Published On: 2024-02-08]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bone Metastasis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Bone Metastasis Market, highlighting leading vendors and their innovative profiles. These include A.S. Lifesciences, AdvaCare Pharma USA, Aetos Pharma Private Limited, Amgen Inc., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Beacon Pharmaceuticals PLC., Cipla Limited, Dr. Reddy's Laboratories Ltd., Encapsula NanoSciences LLC, Fresenius Kabi AG, Getwell Pharma India Private Limited, Global Calcium PVT LTD, GLS Pharma Pvt. Ltd., LEXICARE PHARMA PVT. LTD., Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, and Zydus Lifesciences Limited.
Market Segmentation & Coverage